Alloy BBB and Consumer Complaint Trends: An Independent Review for Women

What Alloy Is and How It Works

Alloy is a women-only telehealth company founded in 2019 that prescribes and ships hormone therapy, hair-loss treatments, and sexual-health medications directly to patients. The model is cash-pay, subscription-style. You complete an intake questionnaire, a clinician reviews it asynchronously or via video, and medication arrives by mail. No insurance is accepted.

The platform targets women in perimenopause and post-menopause, two life stages that are chronically underserved by traditional primary care. That gap is real, and D2C menopause companies have stepped into it quickly. Speed and convenience matter. So does knowing whether the company prescribing your estradiol is operating safely and honestly.

What Alloy Prescribes

Alloy's formulary, as publicly described, includes:

• Systemic HRT: oral estradiol, transdermal estradiol patches and gels, micronized progesterone (Prometrium or generic)
• Local vaginal therapy: low-dose vaginal estradiol cream or tablet for genitourinary syndrome of menopause (GSM)
• Hair loss: oral minoxidil, topical minoxidil, spironolactone, finasteride (for women)
• Sexual health: sildenafil for women (off-label), ospemifene for GSM-related dyspareunia

Each of these carries specific risks in women that change by hormonal status and life stage. We cover those below.

The D2C Model: Convenience vs. Continuity

The asynchronous questionnaire-first model means many women never speak to a clinician by video before their first prescription ships. That is a structural feature, not a bug unique to Alloy. But it matters for hormone therapy, where a missed history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, or active thromboembolism represents a contraindication to systemic estrogen. The quality of the intake questionnaire is doing clinical work that is normally done face-to-face.

Alloy BBB Profile: What the Data Actually Shows

The Better Business Bureau is a private nonprofit, not a government regulator. Its ratings reflect complaint volume relative to company size, responsiveness to those complaints, and whether the company meets BBB's accreditation standards. A high BBB rating does not mean a company is safe; a low rating does not mean it is fraudulent. Read it as one signal among several.

Accreditation Status

As of mid-2025, Alloy Women does not appear as an accredited BBB business. Accreditation is voluntary and requires a fee plus agreement to BBB's standards of trust. Many legitimate companies, including large telehealth platforms, choose not to pursue it. Non-accreditation is not a red flag on its own.

Complaint Volume and Categories

BBB complaint data for Alloy shows a relatively small number of filed complaints for a company of its size and customer base, but the pattern within those complaints is informative. Recurring themes across consumer-review platforms (BBB, Trustpilot, Reddit r/Menopause) include:

1. Billing and subscription cancellation difficulty. The most cited friction point is being charged after attempting to cancel. Some users report needing multiple contacts to stop recurring charges.
2. Shipping delays and pharmacy coordination problems. Medications routed through third-party specialty pharmacies sometimes arrive late or require the patient to chase logistics.
3. Prescription denial without clear explanation. A subset of users report that their intake was denied and they received no clinical rationale. For a woman experiencing vasomotor symptoms affecting sleep and quality of life, a denial without explanation is not just frustrating; it delays care.
4. Difficulty reaching a clinician for follow-up questions. Asynchronous messaging platforms vary in response time. Several complaints mention waiting days for answers to questions about side effects.

A useful framework for evaluating any D2C prescriber: separate operational complaints (billing, shipping, customer service) from clinical-safety complaints (wrong drug prescribed, contraindication missed, no follow-up for adverse effects). Alloy's publicly visible complaints skew heavily operational. Operational failures are fixable and do not necessarily indicate unsafe prescribing. Clinical-safety failures are a different category entirely.

What the BBB File Does Not Tell You

BBB data represents only consumers who chose to file a BBB complaint. Most dissatisfied customers do not. The absence of clinical-safety complaints in the BBB file does not mean clinical errors have not occurred; it means they have not been routed there. State medical board complaints, FDA MedWatch reports, and FTC complaints are separate systems entirely.

Is Alloy Legit? Regulatory and Licensing Review

"Legit" can mean several things: legally operating, clinically sound, or financially trustworthy. Each deserves a separate answer.

Legal Operating Status

Alloy prescribers are licensed clinicians in their respective states. Telehealth prescribing of controlled substances (which Alloy's formulary largely does not include, with the exception of some compounded products) falls under state medical practice acts and, for controlled substances, DEA telemedicine rules. Estradiol and progesterone are not controlled substances. Finasteride and spironolactone are not controlled substances. FDA regulations governing drug advertising and off-label promotion apply to how Alloy markets its products, as they do to any prescriber or pharmacy.

There is no public record, as of this writing, of FDA warning letters issued to Alloy, FTC enforcement actions against Alloy, or state medical board actions against Alloy-affiliated prescribers. Absence of enforcement is not proof of perfect compliance, but it is meaningful information.

LegitScript and Pharmacy Verification

LegitScript is the verification service used by Google, Visa, and major payment processors to vet online pharmacies and telehealth platforms. Alloy works with third-party pharmacies that are licensed U.S. Pharmacies. Women should confirm that any medication they receive from any telehealth platform bears a label from an identifiable, licensed U.S. Pharmacy, includes a prescriber name, and arrives in tamper-evident packaging. If it does not, that is a red flag regardless of the platform's brand reputation.

Compounding: A Specific Watchpoint

Some Alloy prescriptions may be filled by 503A compounding pharmacies, particularly for low-dose vaginal estrogen formulations or combination products not available commercially. FDA does not pre-approve compounded drugs for safety or efficacy. This does not make compounded hormones dangerous by default, but it does mean the woman using them carries more of the verification burden. Ask which pharmacy is compounding your prescription. Check that pharmacy's state board license. The NABP CPE accreditation list is a useful starting point.

Sex-Specific Physiology and the Drugs Alloy Prescribes

Any review of a women's telehealth platform must address the pharmacology of what it prescribes. Here is what women at different life stages need to know about Alloy's core products.

Estradiol: Route, Dose, and Hormonal Status

Oral estradiol undergoes significant first-pass hepatic metabolism, raising SHBG and, at higher doses, triglycerides and C-reactive protein. Transdermal estradiol bypasses the liver and carries a lower VTE risk than oral formulations, an important consideration for perimenopausal women who may have baseline cardiovascular risk factors. The Menopause Society 2023 position statement states that for healthy women under 60 and within 10 years of menopause, the benefits of hormone therapy for vasomotor symptoms and quality of life generally outweigh the risks.

During perimenopause: Women still ovulating need to know that systemic HRT does not provide reliable contraception. Cycles may be irregular but ovulation can occur. Pregnancy on top of systemic HRT doses of estradiol is a clinical problem.

Post-menopause: Standard transdermal estradiol doses range from 0.025 mg to 0.1 mg per day. Alloy's prescribing should stay within this range unless there is documented clinical rationale for deviation.

Progesterone: Why It Matters for Women with a Uterus

Any woman with an intact uterus receiving systemic estrogen must also receive progestogen to protect the endometrium from hyperplasia. The Women's Health Initiative trial used medroxyprogesterone acetate (MPA); current guidance from ACOG and The Menopause Society favors micronized progesterone (Prometrium) as having a more favorable safety and tolerability profile, particularly for sleep and mood. Women who have had a hysterectomy do not require progestogen. A D2C platform prescribing estrogen alone to a woman with an intact uterus, without asking about uterine status, would be a serious clinical gap.

Vaginal Estradiol for GSM

Genitourinary syndrome of menopause (GSM) affects up to 50% of post-menopausal women and includes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. Low-dose vaginal estradiol (0.01% cream, 10-mcg tablet, or the Femring ring) acts locally with minimal systemic absorption. ACOG and The Menopause Society agree that even women with a history of breast cancer may be candidates for low-dose vaginal estrogen when non-hormonal options have failed, in consultation with their oncologist.

Hair Loss Medications

Finasteride (1 mg oral) in women: Finasteride is a 5-alpha-reductase inhibitor used off-label for female pattern hair loss (androgenetic alopecia). A 2019 Dermatology study found benefit in post-menopausal women but evidence in pre-menopausal women is limited. Finasteride is a Category X teratogen in pregnancy and is absolutely contraindicated in women who are pregnant or may become pregnant. See the pregnancy and contraception section below.

Spironolactone: Commonly prescribed for hormonal hair loss and hormonal acne in women with PCOS or hyperandrogenism. Effective and well-tolerated in most reproductive-age women, but it also carries pregnancy risk (see below).

Oral minoxidil (0.625 mg to 2.5 mg in women): Increasingly prescribed off-label for female pattern hair loss. Lower doses are used in women than men due to higher sensitivity. Side effects include hypertrichosis and, rarely, fluid retention.

Sildenafil for Women

Off-label use of sildenafil for female sexual arousal disorder and hypoactive sexual desire disorder (HSDD) remains an area where evidence is genuinely thin. A 2008 Cochrane review found sildenafil improved physiological arousal in women with sexual dysfunction but did not consistently improve subjective desire or satisfaction. Women have been historically underrepresented in trials of PDE5 inhibitors, and most dose data is extrapolated from male studies. If Alloy is prescribing sildenafil for women, patients should understand this is off-label use with limited female-specific dose-response data.

Pregnancy, Lactation, and Contraception: What Every User Must Know

This section applies to any drug article on WomanRx. For Alloy's product categories, the pregnancy and lactation implications are significant.

Systemic Estrogen and Progesterone

Systemic HRT doses of estradiol are not indicated in pregnancy and should not be used by women who are pregnant. FDA labeling for estradiol products carries contraindication in known or suspected pregnancy. Perimenopausal women who still have menstrual cycles, even irregular ones, may ovulate. Alloy's intake process should include explicit questioning about contraception status and last menstrual period. Women who are perimenopausal and using systemic HRT need a reliable contraceptive method unless they have been confirmed post-menopausal (no menses for 12 consecutive months) or have had surgical menopause.

Micronized progesterone at HRT doses is also not used in pregnancy. High-dose progesterone supplementation for luteal support in ART is a different clinical context entirely.

Finasteride: Contraindication in Pregnancy is Absolute

Finasteride is FDA Pregnancy Category X. Even skin contact with crushed finasteride tablets poses a theoretical risk to a male fetus. Women of reproductive potential prescribed finasteride by any platform, including Alloy, must use effective contraception for the duration of treatment. This is non-negotiable. Any D2C platform prescribing finasteride to a woman without confirming contraception status or post-menopausal status is operating outside of safe prescribing practice.

Spironolactone in Pregnancy

Spironolactone is classified as FDA Pregnancy Category C with animal data showing feminization of male fetuses at high doses. It is generally avoided in pregnancy. Women of reproductive age prescribed spironolactone should use contraception, and this is standard practice in dermatology and gynecology.

Lactation

Estradiol passes into breast milk and may suppress lactation. It is generally not recommended during breastfeeding. This is unlikely to be a concern for Alloy's post-menopausal target demographic, but perimenopausal women who are postpartum and experiencing early menopausal symptoms should disclose breastfeeding status during intake.

Finasteride transfer to breast milk has not been adequately studied. Given its teratogenic potential, it should not be used during lactation as a precaution.

Who Alloy May Be Right For (and Who Should Think Twice)

Potentially a Good Fit

• Post-menopausal women with moderate vasomotor symptoms (hot flashes, night sweats) who have no contraindications to systemic estrogen and want convenient access without waiting months for a gynecology appointment
• Women with confirmed GSM seeking low-dose vaginal estrogen with a straightforward clinical picture
• Post-menopausal women with female pattern hair loss who are not of reproductive potential
• Women who have a primary clinician managing their cardiovascular and metabolic health and want a specialist platform for menopausal symptom management specifically

Worth Pausing For

• Perimenopausal women still menstruating who need to discuss contraception simultaneously with HRT, since Alloy's asynchronous model may not fully address this intersection
• Women with a history of estrogen-receptor-positive breast cancer, where systemic HRT is generally contraindicated per ACOG Practice Bulletin 126 and should involve oncology coordination that a D2C platform cannot provide
• Women with undiagnosed vaginal bleeding, where endometrial pathology must be ruled out before starting estrogen
• Women with a history of DVT or PE, given the VTE risk associated with oral estrogen especially
• Women seeking finasteride who have not confirmed effective contraception and are of reproductive potential
• Women with complex comorbidities (e.g., active liver disease, uncontrolled hypertension, prior thrombotic events) where HRT risk-benefit analysis requires in-person evaluation

How to Evaluate Any D2C Menopause Platform

Whether you are considering Alloy or any competitor, these are the questions that matter clinically.

Ask Before You Subscribe

1. Does the intake process ask about personal and family history of breast cancer, blood clots, stroke, and liver disease?
2. Is there a licensed clinician in your state who will review your intake and whose name appears on your prescription?
3. Does the platform ask about uterine status before prescribing systemic estrogen?
4. Is there a mechanism to reach your prescriber for follow-up questions, and what is the documented response time?
5. Does the platform ask about contraception status before prescribing teratogenic drugs such as finasteride?
6. Which pharmacy fills your prescription, and is it a licensed U.S. Pharmacy?

The Menopause Society's "Menopause Practitioner Locator" can help you find a certified menopause specialist if you prefer in-person or hybrid care.

Filing a Complaint: Where to Go If Something Goes Wrong

If you experience a problem with Alloy or any telehealth prescriber, the BBB is the least powerful option available to you. More effective routes:

• State Medical Board: File against the individual prescriber. Each state has its own board. The Federation of State Medical Boards maintains a directory.
• State Pharmacy Board: File against the dispensing pharmacy.
• FDA MedWatch: Report adverse drug events at fda.gov/safety/medwatch. This is the mechanism through which post-market drug safety signals are tracked.
• FTC: Report deceptive advertising at ftc.gov/complaint.
• Your credit card company: For unauthorized charges, a chargeback is often faster than a BBB complaint.

The Evidence Gap in Women's Telehealth

Women have been historically underrepresented in cardiovascular and pharmacokinetic trials, a problem documented extensively in the literature. The rush of D2C platforms into the menopause space is partly filling a genuine access gap, but it also means that prescribing decisions that were previously made with in-person clinical nuance are now being made by algorithms and questionnaires. Neither the BBB nor any other consumer-complaint platform tracks whether a contraindication was missed. That gap is real, and it is the user's burden to ask the right questions upfront.

The Menopause Society's 2023 position statement is the single most evidence-based document available to guide menopause HRT decisions. Print it, read the patient-facing summary, and bring it to any telehealth intake or in-person appointment.